Why the study?
Does rivaroxaban prevent stroke/systemic embolism, major bleeding, or death in patients with non-valvular atrial fibrillation?
Does rivaroxaban prevent stroke/systemic embolism, major bleeding, or death in patients with non-valvular atrial fibrillation?
In a large, international prospective observational study, rivaroxaban demonstrated high safety and effectiveness, with over 96% of patients free from stroke, major bleeding, or death at one year.
Supports broad rivaroxaban use in NVAF; extends prospective cohort data while leaving randomized comparisons open.
XANTUS is the first large, international prospective study to describe rivaroxaban use in a broad patient population with non-valvular atrial fibrillation. Out of 6784 patients, over 96% patients receiving rivaroxaban did not experience any of the outcomes of stroke/systemic embolism, treatment-emergent major bleeding or all-cause death. In XANTUS, rivaroxaban demonstrated low rates of stroke/ systemic embolism and major bleeding, including intracranial and gastrointestinal bleeding. Treatment persistence and patient satisfaction were high, namely 80% of patients remained on rivaroxaban and 75% reported they were satisfied with their treatment at one year.
No takes yet. Share an insight, caveat, or question.
Postuła et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: